Bristol's Opdivo reduces risk of death from common lung cancer

Chicago May 29 (Reuters) - Bristol-Myers Squibb Co's drug, Opdivo, improved survival for patients with the most common form of lung cancer, nearly doubling survival for those with high levels of a specific protein in their tumors compared with chemotherapy, according to clinical trial results presented on Friday.